- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Tyra Biosciences stock price target raised to $55 from $35 at Raymond James | 4 | Investing.com | ||
| 23.01. | Tyra Biosciences: Piper Sandler erhöht Kursziel wegen Wachstumsaussichten auf 42 US-Dollar | 1 | Investing.com Deutsch | ||
| 23.01. | Piper Sandler raises Tyra Biosciences stock price target to $42 on growth outlook | 2 | Investing.com | ||
| 16.12.25 | Wedbush raises Tyra Biosciences stock price target to $37 on pipeline potential | 1 | Investing.com | ||
| 04.12.25 | Goldman Sachs initiates coverage of Tyra Biosciences stock with Early-Stage Biotech rating | 1 | Investing.com | ||
| 01.12.25 | Tyra Biosciences appoints two key executives to leadership team | 1 | Investing.com | ||
| TYRA BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 01.12.25 | Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer | 151 | PR Newswire | CARLSBAD, Calif., Dec. 1, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation... ► Artikel lesen | |
| 01.12.25 | Tyra Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 06.11.25 | Tyra Biosciences GAAP EPS of -$0.50 beats by $0.05 | 1 | Seeking Alpha | ||
| 05.11.25 | Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights | 115 | PR Newswire | - Dosed first patients with dabogratinib in BEACH301 and SURF302; interim results from both studies expected in 2026 -
- Expanded development of dabogratinib... ► Artikel lesen | |
| 10.09.25 | Oppenheimer raises Tyra Biosciences stock price target to $36 on market potential | 3 | Investing.com | ||
| 22.08.25 | Tyra Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.08.25 | Achondroplasie-Studie: Tyra Biosciences behandelt erstes Kind mit Dabogratinib | 4 | Investing.com Deutsch | ||
| 21.08.25 | Tyra Biosciences doses first child in achondroplasia treatment trial | 1 | Investing.com | ||
| 21.08.25 | Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia | 236 | PR Newswire | -Dabogratinib is the only oral FGFR3-selective inhibitor in clinical development for achondroplasia-
-Initial results from safety sentinel cohort expected in 2H... ► Artikel lesen | |
| 14.08.25 | Tyra Biosciences, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 14.08.25 | Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights | 686 | PR Newswire | - Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) -
- Cash, cash equivalents, and marketable securities of $296.3... ► Artikel lesen | |
| 30.06.25 | Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302) | 359 | PR Newswire | -TYRA-300 is the only orally administered investigational agent in clinical development for IR NMIBC-
-Initial 3-month complete response (CR) data expected to be... ► Artikel lesen | |
| 08.05.25 | Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights | 469 | PR Newswire | - BEACH301 study of TYRA-300 for Pediatric Achondroplasia (ACH) Open for Enrollment -
- Initiated patient dosing in SURF431 study of TYRA-430 for hepatocellular... ► Artikel lesen | |
| 27.03.25 | Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights | 386 | PR Newswire | - Three INDs cleared by US FDA for TYRA's proprietary precision small molecules -
- TYRA-300 to be evaluated in three Phase 2 studies: SURF302 for Intermediate Risk... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 44,620 | +0,64 % | Adidas schmiert ab, Qiagen zieht an: DAX-Ausblick | Der DAX hat eine volatile Woche hinter sich. Unter dem Strich büßte das größte deutsche Börsenbarometer knapp 400 Punkte ein und schloss -1,57% tiefer mit 24.900 Punkten. Die höchsten Verluste gab es... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 314,30 | +0,01 % | H.C. Wainwright raises Praxis Precision Medicines stock price target to $1,245 | ||
| NUVALENT | 102,89 | +0,45 % | Royalty Pharma plc: Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an... ► Artikel lesen | |
| NURIX THERAPEUTICS | 16,520 | -6,08 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update | First patients dosed in DAYBreak registrational program for bexobrutideg in relapsed/refractory CLLPresented Phase 1 results at ASH 2025 that support bexobrutideg's potential best-in-class profile... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 14,290 | -3,77 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 25,720 | -1,30 % | Olema Oncology Announces Departure of Chief Operating and Financial Officer | SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema", or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 65,42 | -6,52 % | Apogee Therapeutics: Empfehlung liefert +129% in 6 Monaten | Im Juli letzten Jahres präsentierten wir im Rahmen unserer Berichterstattung und innerhalb unserer erfolgreichen Community die Aktie von Apogee Therapeutics als heißen Kauftipp. Grundlage war eine ausgeprägte... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 36,520 | -0,92 % | How Harmony Biosciences Can Prove Its Skeptics Wrong | ||
| STRUCTURE THERAPEUTICS | 88,44 | +1,48 % | Structure Therapeutics gains on report suggesting it may be a top takeover target | ||
| SUMMIT THERAPEUTICS | 14,460 | -6,10 % | Summit Therapeutics: FDA akzeptiert Zulassungsantrag für Lungenkrebsmedikament Ivonescimab | ||
| BIONTECH | 95,80 | -0,21 % | BASF unter DRUCK! KAUFEMPFEHLUNGEN für BioNTech und WashTec Aktie! | Marktführerschaft, Effizienzsteigerung, Dividende und Aktienrückkauf - alles gute Gründe, um die Aktie von WashTec zu kaufen. Diese Einschätzung teilen auch die Analysten von MM Warburg. Ihre Gewinnschätzungen... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 31,110 | -2,75 % | Block & Leviton LLP: Travere Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow TVTX Investors to Recover Losses | Boston, Massachusetts--(Newsfile Corp. - January 16, 2026) - Block & Leviton is investigating Travere Therapeutics, Inc. (NASDAQ: TVTX) for potential securities law violations. Investors who have... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,58 | +0,01 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ERASCA | 10,525 | +2,09 % | Guggenheim More Than Doubles Erasca (ERAS) PT Following Clinical Progress and Updated Pipeline Models | ||
| ADMA BIOLOGICS | 17,300 | +1,70 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen |
Das Unternehmen TYRA BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -4,62 % bei einem Aktienkurs von 30,845 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TYRA BIOSCIENCES INC finden Sie auf Wallstreet Online.